Why the study?
Does once-daily subcutaneous vosoritide improve annualized growth velocity in children with achondroplasia?
Does once-daily subcutaneous vosoritide improve annualized growth velocity in children with achondroplasia?
Once-daily subcutaneous vosoritide provides a sustained increase in annualized growth velocity with a mild side-effect profile in children with achondroplasia.
Answers are grounded in this paper and cite their sources.
May support vosoritide evaluation in achondroplasia; leaves open randomized confirmation before practice change.
In children with achondroplasia, once-daily subcutaneous administration of vosoritide was associated with a side-effect profile that appeared generally mild. Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov numbers, NCT01603095, NCT02055157, and NCT02724228.).
No takes yet. Share an insight, caveat, or question.
Savarirayan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: